https://yk-health.org/index.php?action=history&feed=atom&title=Tranexamic_acid_%28TXA%29_for_Trauma
Tranexamic acid (TXA) for Trauma - Revision history
2026-04-18T20:52:20Z
Revision history for this page on the wiki
MediaWiki 1.39.5
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8597&oldid=prev
AndyS at 05:17, 17 December 2021
2021-12-17T05:17:53Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 05:17, 17 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l14">Line 14:</td>
<td colspan="2" class="diff-lineno">Line 14:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute). This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, among the subset of patients with intracranial hemorrhage on initial head CT, the 2g bolus group had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group (5% versus 2% and 2%, respectively), but this was not associated with any long term effects.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref><ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute). This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, among the subset of patients with intracranial hemorrhage on initial head CT, the 2g bolus group had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group (5% versus 2% and 2%, respectively), but this was not associated with any long term effects.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43<ins style="font-weight: bold; text-decoration: none;">. PMID:[https://pubmed.ncbi.nlm.nih.gov/32969002/ 32969002]</ins>. https://www.jsomonline.org/AllArticles.php#Article1037</ref><ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8596&oldid=prev
AndyS at 01:38, 17 December 2021
2021-12-17T01:38:44Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 01:38, 17 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l9">Line 9:</td>
<td colspan="2" class="diff-lineno">Line 9:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== ALTERNATE DOSING ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== ALTERNATE DOSING ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The U.S. Military is now recommending a '''<u>SINGLE DOSE</u> of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name=<del style="font-weight: bold; text-decoration: none;">"DrewAutenCap2020"</del>><del style="font-weight: bold; text-decoration: none;">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: </del>TCCC <del style="font-weight: bold; text-decoration: none;">Proposed Change 20-02</del>. <del style="font-weight: bold; text-decoration: none;">J Spec Oper Med</del>. 2020<del style="font-weight: bold; text-decoration: none;">;20(3):36-43</del>. https://www.<del style="font-weight: bold; text-decoration: none;">jsomonline</del>.<del style="font-weight: bold; text-decoration: none;">org</del>/<del style="font-weight: bold; text-decoration: none;">AllArticles</del>.<del style="font-weight: bold; text-decoration: none;">php#Article1037</del></ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>The U.S. Military is now recommending a '''<u>SINGLE DOSE</u> of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name=<ins style="font-weight: bold; text-decoration: none;">TCCCGuideline</ins>>TCCC <ins style="font-weight: bold; text-decoration: none;">Guidelines</ins>. <ins style="font-weight: bold; text-decoration: none;">Deployed Medicine</ins>. <ins style="font-weight: bold; text-decoration: none;">Published November 5, </ins>2020. <ins style="font-weight: bold; text-decoration: none;">Accessed November 23, 2021. [</ins>https://www.<ins style="font-weight: bold; text-decoration: none;">deployedmedicine</ins>.<ins style="font-weight: bold; text-decoration: none;">com</ins>/<ins style="font-weight: bold; text-decoration: none;">market/11/content/40 eBook] [https://learning-media</ins>.<ins style="font-weight: bold; text-decoration: none;">allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF]</ins></ref></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute).<del style="font-weight: bold; text-decoration: none;"><ref>TCCC Guidelines. Deployed Medicine. Published November 5, 2020. Accessed November 23, 2021. [https://www.deployedmedicine.com/market/11/content/40 eBook] [https://learning-media.allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF]</ref> </del> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, among the subset of patients with intracranial hemorrhage on initial head CT, the 2g bolus group had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group (5% versus 2% and 2%, respectively), but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute). This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, among the subset of patients with intracranial hemorrhage on initial head CT, the 2g bolus group had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group (5% versus 2% and 2%, respectively), but this was not associated with any long term effects.<ins style="font-weight: bold; text-decoration: none;"><ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref></ins><ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8595&oldid=prev
AndyS at 21:31, 16 December 2021
2021-12-16T21:31:13Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 21:31, 16 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l14">Line 14:</td>
<td colspan="2" class="diff-lineno">Line 14:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute).<ref>TCCC Guidelines. Deployed Medicine. Published November 5, 2020. Accessed November 23, 2021. [https://www.deployedmedicine.com/market/11/content/40 eBook] [https://learning-media.allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF]</ref> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, among the subset of patients with intracranial hemorrhage on initial head CT, the 2g bolus group had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group, but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute).<ref>TCCC Guidelines. Deployed Medicine. Published November 5, 2020. Accessed November 23, 2021. [https://www.deployedmedicine.com/market/11/content/40 eBook] [https://learning-media.allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF]</ref> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, among the subset of patients with intracranial hemorrhage on initial head CT, the 2g bolus group had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group <ins style="font-weight: bold; text-decoration: none;">(5% versus 2% and 2%, respectively)</ins>, but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8594&oldid=prev
AndyS at 21:27, 16 December 2021
2021-12-16T21:27:45Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 21:27, 16 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l14">Line 14:</td>
<td colspan="2" class="diff-lineno">Line 14:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute).<ref>TCCC Guidelines. Deployed Medicine. Published November 5, 2020. Accessed November 23, 2021. [https://www.deployedmedicine.com/market/11/content/40 eBook] [https://learning-media.allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF]</ref> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, the subset of patients with intracranial hemorrhage on initial head CT had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group, but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute).<ref>TCCC Guidelines. Deployed Medicine. Published November 5, 2020. Accessed November 23, 2021. [https://www.deployedmedicine.com/market/11/content/40 eBook] [https://learning-media.allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF]</ref> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, <ins style="font-weight: bold; text-decoration: none;">among </ins>the subset of patients with intracranial hemorrhage on initial head CT<ins style="font-weight: bold; text-decoration: none;">, the 2g bolus group </ins>had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group, but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ref> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8593&oldid=prev
AndyS at 21:25, 16 December 2021
2021-12-16T21:25:15Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 21:25, 16 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l9">Line 9:</td>
<td colspan="2" class="diff-lineno">Line 9:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== ALTERNATE DOSING ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== ALTERNATE DOSING ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The U.S. Military is now recommending a '''<u>SINGLE DOSE</u> of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037<del style="font-weight: bold; text-decoration: none;"></ref> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, the subset of patients with intracranial hemorrhage on initial head CT had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group, but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</del></ref> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>The U.S. Military is now recommending a '''<u>SINGLE DOSE</u> of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DISCUSSION ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute).<ref>TCCC Guidelines. Deployed Medicine. Published November 5, 2020. Accessed November 23, 2021. [https://www.deployedmedicine.com/market/11/content/40 eBook] [https://learning-media.allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF]</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>In the fall of 2020 the United States Department of Defense (DOD) Committee on Tactical Combat Casualty Care (CoTCCC)<ref>Committee on Tactical Combat Casualty Care (CoTCCC) - Joint Trauma System. Accessed November 23, 2021. https://jts.amedd.army.mil/index.cfm/committees/cotccc</ref> updated the Tactical Combat Casualty Care (TCCC) guidelines to specify that TXA should be administered as a single dose of 2 grams slow IV/IO push (over 1 minute).<ref>TCCC Guidelines. Deployed Medicine. Published November 5, 2020. Accessed November 23, 2021. [https://www.deployedmedicine.com/market/11/content/40 eBook] [https://learning-media.allogy.com/api/v1/pdf/237e56d8-ebc5-4a86-8b8a-70ea0489e8c2/contents PDF<ins style="font-weight: bold; text-decoration: none;">]</ref> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, the subset of patients with intracranial hemorrhage on initial head CT had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group, but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958</ins>]</ref> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8592&oldid=prev
AndyS at 21:08, 16 December 2021
2021-12-16T21:08:33Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 21:08, 16 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">__TOC__</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><br></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8591&oldid=prev
AndyS at 21:05, 16 December 2021
2021-12-16T21:05:02Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 21:05, 16 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7">Line 7:</td>
<td colspan="2" class="diff-lineno">Line 7:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== ALTERNATE DOSING ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== ALTERNATE DOSING ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The U.S. Military is now recommending a '''<u>SINGLE DOSE</u> of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>The U.S. Military is now recommending a '''<u>SINGLE DOSE</u> of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037<ins style="font-weight: bold; text-decoration: none;"></ref> This adoption of 2 gram bolus dosing was mainly driven by the outcomes a recent civilian, multi-center RCT which compared the 2 gram bolus dosing (n=345) to either conventional dosing (n=312) or placebo (n=309) in the prehospital phase of care of patients with a head injury and GCS of 12 or less; though the primary outcome showed no difference, the subset of patients with intracranial hemorrhage on initial head CT had a 35 percent decrease in 28-day mortality (18% versus 28% and 28%, respectively). Additionally, the only adverse effect was increased "seizure like activity" in the 2g bolus dose group, but this was not associated with any long term effects.<ref>Rowell SE, Meier EN, McKnight B, et al. Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury. JAMA. 2020;324(10):961-974. doi:[https://doi.org/10.1001/jama.2020.8958 10.1001/jama.2020.8958]</ins></ref> </div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8590&oldid=prev
AndyS at 19:42, 16 December 2021
2021-12-16T19:42:56Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 19:42, 16 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><br></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== CONVENTIONAL DOSING ==</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">One gram in 100mL saline infused over 10 minutes (initiated within 3 hours of injury), followed by one gram over 8 hours.</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><br></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><br></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>== DOSING ==</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>== <ins style="font-weight: bold; text-decoration: none;">ALTERNATE </ins>DOSING ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>'''<del style="font-weight: bold; text-decoration: none;">Single dose </del>of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">The U.S. Military is now recommending a </ins>'''<ins style="font-weight: bold; text-decoration: none;"><u>SINGLE DOSE</u> </ins>of 2 grams slow IV/IO push''' (over 1 minute) within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8589&oldid=prev
AndyS at 06:19, 10 December 2021
2021-12-10T06:19:18Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 06:19, 10 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2">Line 2:</td>
<td colspan="2" class="diff-lineno">Line 2:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DOSING ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== DOSING ==</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>2 grams slow IV/IO push within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">'''Single dose of </ins>2 grams slow IV/IO push<ins style="font-weight: bold; text-decoration: none;">''' (over 1 minute) </ins>within 3 hours of injury.<ref name="DrewAutenCap2020">Drew B, Auten JD, Cap AP, et al. The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. J Spec Oper Med. 2020;20(3):36-43. https://www.jsomonline.org/AllArticles.php#Article1037</ref></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div><br></div></td></tr>
</table>
AndyS
https://yk-health.org/index.php?title=Tranexamic_acid_(TXA)_for_Trauma&diff=8585&oldid=prev
AndyS at 22:29, 9 December 2021
2021-12-09T22:29:29Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 22:29, 9 December 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l36">Line 36:</td>
<td colspan="2" class="diff-lineno">Line 36:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br/></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== REFERENCES ==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== REFERENCES ==</div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><references/></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><br></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><br></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"><small>Author[s]:</small><br></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Andrew W. Swartz, MD<br></ins></div></td></tr>
</table>
AndyS